Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

BIG PICTURE - Amphion Innovations has high hopes for partner Kromek

Amphion Innovations is advancing on several fronts and has particularly great hopes for partner company Kromek, which it expects to significantly grow in value
BIG PICTURE - Amphion Innovations has high hopes for partner Kromek

Amphion Innovations (LON:AMP) is advancing on several fronts and has particularly great hopes for partner company Kromek, which it expects to significantly grow in value.

Amphion has lots of irons in the fire but essentially its business model is simple - it has stakes in seven companies and the goal is to support and develop their value. By default Amphion grows its value at the same time.  

In Kromek, a pioneering imaging company, it has an 11.6% stake worth £6.2 million - so we're talking big numbers here.

The financing agreement, announced today, in the form of a new US$2 million share-backed loan from an institutional lender, Amphion says, will allow it to advance these partner companies and its long-running intellectual property (IP)  licensing programme.

It comes after a set-back in March this year, when Kromek, which only floated on AIM in October 2013, said revenues for its year to end April would be "significantly below the market's expectations" causing the firm's shares and thus its value to plummet.

It blamed delays in a number of large contracts and timing issues for the missed forecasts.

Richard Morgan, Amphion's chief executive and Kromek chairman, told Proactive Investors it was fundamentally a matter of "slippage" and not  altogether surprising that forecasting at Kromek had gone awry.

"It's quite hard to get the forecasting right when growing so rapidly off such a small base," he said, also pointing to Kromek’s limited experience of some of the markets it operated in, and he added that it was not surprising that the stock market reacted negatively to the announcement.  

However, Morgan suggested the next announcement just a week after the trading statement of a long term contract with a Chinese manufacturer of x-ray diagnostics equipment, told a different story.

That deal provides for revenues of US$1.4 million and US$10.2 million in years 2014-15 and 2015-16 respectively and the overall value of the contract over the next seven years is up to US$159 million.

Meanwhile, research group Equity Development noted recently that the group had won a "plethora" of orders since listing amounting to £8 million in the first half of 2014 alone.

The key factor, reckons Morgan, is whether the Kromek platform is working, and all signs clearly point to the fact that it is.

"I think the value of Kromek's technology platform is incredibly strong and much underappreciated by the market," he said, adding he expected to see the holding be of considerable value to Amphion in a year or two.

Elsewhere, a key strand of Amphion's story, is its IP licensing  programme, managed by subsidiary DataTern.

There are currently 19 separate defendants in separate cases where Amphion is taking legal action against patent infringement.

And there was a boost in April, when DataTern received what it called a "good ruling" in the US Appeals court in proceedings involving giants SAP and Microsoft, which should help revive the momentum of the programme, which has been running for seven years. 

The loan financing allows the firm access to capital to keep such programmes going and it is the type of financing which, rather than an equity raise, is less dilutive to shareholders.

It can be paid back in cash or Amphion or Kromek shares and as Morgan said in the announcement, the firm hopes not to lose any Kromek shares.

"We believe the very bright future of the company (Kromek) should be reflected in a much higher valuation in due course.  Amphion currently has some exciting developments underway, but in order to support our partner companies and progress our IP licensing programme we need access to additional capital.  

"This new financing will help Amphion to bring those developments to fruition.  I look forward to being able to report progress in the coming months and we believe that should allow us to retain our entire holding in Kromek."

So the Amphion story remains a multi-faceted one and looks set to have many promising developments in the not too distant future.

Amphion shares are unchanged today at 2.635p.

View full AMP profile View Profile

Amphion Innovations Plc Timeline

Related Articles

Picture of hospital operating room
June 06 2017
The tech/bio company investor may have an image problem, but definitely not an imaging problem
1505724201_learningtechnology.jpg
September 18 2017
Broker Numis thinks the benefits of the NetDimensions deal will be felt in the fourth quarter
picture of virtual reality headset
October 24 2017
New shares sold through a book build exercise in about two hours at a tiny discount to the market price to rasie £75mln

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use